GFH276

Phase 2Small molecule

GGenfleet Therapeutics (Shanghai) Inc.

GFH276 is one of 94 small molecule programs targeting Advanced Solid Tumors Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced Solid Tumors CancerNot yet recruiting

Pancreatic CancerNot yet recruiting

Advanced Solid TumorsNot yet recruiting

Advanced Solid Tumors CancerPreclinical

Not yet recruiting

Pancreatic CancerPhase 2

Not yet recruiting

Advanced Solid TumorsPhase 2

Not yet recruiting

Competition

Competitive Landscape

335 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

Medrol

Pfizer

Preclinical

1 2

Byetta

AstraZeneca

Preclinical

1 3

GFH276

GGenfleet Therapeutics (Shanghai) Inc.

Phase 2

1 4

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

1 5

Ayvakit Sprinkle

MMemorial Sloan Kettering Cancer Center

Preclinical

1 6

Xylocaine

MMEDRx USA, Inc.

Preclinical

1 7

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 8

Active Comparator

Moderna

Preclinical

1 9

Sulfonylureas

Eli Lilly

Preclinical

1 10

PEG-Rhg-CSF

CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1/2Not yet recruiting

Advanced Solid Tumors

NCT07198321

Q3 2028

PreclinicalNot yet recruiting

Advanced Solid Tumors Cancer

NCT07678593

Q3 2029

Phase 2Not yet recruiting

Pancreatic Cancer

NCT07784374

Clinical

Trials by Indication[1]

Advanced Solid Tumors1 trial

A Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid Tumors

Not yet recruiting·GGenfleet Therapeutics (Shanghai) Inc.·Phase 1/2·NCT07198321·450 enrolled

Pancreatic Cancer1 trial

A Phase II, Multicenter, Open-Label, Randomized Controlled Study to Evaluate the Efficacy and Safety of GFH375 in Combination With GFS202A or GFH276 Versus GFH375 Monotherapy in Patients With Previously Treated Locally Advanced Unresectable or Metastatic Pancreatic Cancer Harboring KRAS G12D Mutation

Not yet recruiting·GGenfleet Therapeutics (Shanghai) Inc.·Phase 2·NCT07784374·120 enrolled

Advanced Solid Tumors Cancer1 trial

A Multi-center, Open-label Phase Ib/II Study Exploring the Safety/Tolerability, Pharmacokinetics, and Efficacy of GFH276 in Combination With Cetuximab or Chemotherapy in the Treatment of Patients With Advanced Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation

Not yet recruiting·GGenfleet Therapeutics (Shanghai) Inc.·Preclinical·NCT07678593·222 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for GFH276. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GFH276 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GFH276. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Genfleet Therapeutics (Shanghai) Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: GGenfleet Therapeutics (Shanghai) Inc.

GFH276

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q3 2028

Q3 2029

Trials by Indication[1]

Advanced Solid Tumors1 trial

Pancreatic Cancer1 trial

Advanced Solid Tumors Cancer1 trial

References

Drug Info

Quick Facts

Related News